Fox Run Management’s PTC Therapeutics PTCT Stock Holding History

Fox Run Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$644K	Buy	+7,901	New	+$571K	0.11%	377
2025 Q3	–	Sell	-13,328	Closed	-$651K	–	1179
2025 Q2	$651K	Buy	+13,328	New	+$633K	0.11%	353
2024 Q3	–	Sell	-27,997	Closed	-$856K	–	1046
2024 Q2	$856K	Buy	+27,997	New	+$907K	0.16%	228
2024 Q1	–	Sell	-7,415	Closed	-$204K	–	1003
2023 Q4	$204K	Buy	+7,415	New	+$170K	0.05%	629
2018 Q4	–	Sell	-11,017	Closed	-$518K	–	681
2018 Q3	$518K	Sell	11,017 -987	-8%	-$40.8K	0.23%	166
2018 Q2	$405K	Buy	+12,004	New	+$374K	0.13%	326

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fox Run Management's PTCT Position: Q2 2026 in Review

Fox Run Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 7,901 shares worth $644K. The stake represents 0.11% of the portfolio and ranks #377 among its holdings. This is a return to the name: Fox Run Management previously reported a position in PTCT as recently as Q2 2025.

Fox Run Management first reported a position in PTCT in Q2 2018 and has held it in 6 quarters since. The position peaked at $856K in Q2 2024. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Fox Run Management held 7,901 shares of PTC Therapeutics worth $644K as of Q2 2026.
PTC Therapeutics was a new Fox Run Management position in Q2 2026.
PTC Therapeutics made up 0.11% of Fox Run Management's portfolio in Q2 2026, its #377 holding.
Fox Run Management first reported a position in PTC Therapeutics in Q2 2018 and has held it in 6 quarters since.
Fox Run Management's PTC Therapeutics position peaked at $856K in Q2 2024.
383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.